Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.47 |
| ▸ | AHCY | P23526 | 2/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | AMD1 | P17707 | 1/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14929097 | 0.86 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946120 | 0.86 | ADORA2A (0.46) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL16489873 | 0.80 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15930980 | 0.80 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15746179 | 0.79 | ADORA2A (0.43) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL17231357 | 0.78 | ADORA2A (0.55) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14928579 | 0.77 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL14946103 | 0.77 | ADORA2A (0.42) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL20010218 | 0.77 | ADORA2A (0.45) | ADORA2AADORA2BAHCYDNMT1DNMT3B | |
| SCHEMBL15070300 | 0.77 | ADORA2A (0.48) | ADORA2AADORA2BAHCYDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255129-B2 | Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1 | MODERNA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140141068-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141068-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 | MSH2, RNF168, UBE3A | ADORA2A 3263/4885ADORA2B 4067/4885AHCY 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.